X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the licensing agreement, AstraZeneca will be granted an exclusive global license to research, develop, and commercialize LM-305, a pre-clinical stage antibody drug conjugate (ADC) targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D).
Lead Product(s): LM-305,Dexamethasone
Therapeutic Area: Oncology Product Name: LM-305
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $600.0 million Upfront Cash: $55.0 million
Deal Type: Licensing Agreement May 12, 2023
Details:
TPX-4589 (LM-302) is a potentially first-in-class anti-Claudin18.2 ADC discovered by LaNova that suppresses cell proliferation of gastric and pancreatic cell lines with nanomolar potency in preclinical models. It also has demonstrated efficacy in gastric and pancreatic cancer.
Lead Product(s): LM-302
Therapeutic Area: Oncology Product Name: TPX-4589
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Turning Point Therapeutics
Deal Size: $220.0 million Upfront Cash: $25.0 million
Deal Type: Licensing Agreement May 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
